Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem

Background The treatment of infections caused by OXA-48/CTX-M-coproducing Enterobacterales may be based on new beta-lactam/beta-lactamase inhibitors, such as ceftazidime/avibactam (CZA), or on high dose of meropenem (MER). However, bacterial density at the infection site may vary widely, and the ino...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical microbiology & infectious diseases 2022-05, Vol.41 (5), p.853-858
Hauptverfasser:	Mizrahi, A., Chat, L., Danjean, M., Mory, C., Nguyen Van, JC, de Ponfilly, G. Péan, Caméléna, F., Le Monnier, A., Bercot, B., Birgy, A., Jacquier, H., Pilmis, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Amides Anti-Bacterial Agents Anti-Bacterial Agents - pharmacology Antibiotics Antiinfectives and antibacterials Azabicyclo Compounds - pharmacology beta-Lactamase Inhibitors - pharmacology beta-Lactamases - genetics Biomedical and Life Sciences Biomedicine Brief Report Ceftazidime Ceftazidime - pharmacology Drug Combinations E coli Enterobacterales Enterobacteriaceae - drug effects Enzymes Infections Infectious diseases Inoculum Internal Medicine Life Sciences Medical Microbiology Meropenem Meropenem - pharmacology Microbial Sensitivity Tests Microbiology and Parasitology Pharmacodynamics β Lactamase β-Lactam antibiotics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!